From Compassionate Use to Phase 3 Trial: The Impact of Germany’s PSMA-617 Literature (perspective on “German Multicenter Study Investigating ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients” J Nucl Med. 2017;58:85–90)

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.